Acute oncology: new immunotherapy guidelines
Could cabozantinib be a successful novel therapy for mCRPC?
OS rates and prognostic categories for BRAF-mutated melanoma when treated with combination therapy
What's next for Merkel cell carcinoma trials
Nonmetastatic CRPC: meeting an unmet need